Back to News
Market Impact: 0.25
Goldman Sachs Initiates Coverage of United Therapeutics with Sell Rating
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
Goldman Sachs initiated coverage of United Therapeutics (NASDAQGS: UTHR) with a Sell recommendation on September 24, 2026. The negative analyst initiation is a near-term headwind for the biotechnology company’s shares, though the report provides no price target, valuation rationale, or fundamental forecast changes.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.35
Ticker Sentiment
UTHR-0.70
More News
- JPMorgan upgrades SAP stock rating on AI production shift
- Jefferies downgrades Beta Technologies stock rating on delivery delays
- Rothschild Redburn upgrades Airbnb stock rating on growth momentum
- Goldman says 'the pieces are in place' for a shift in Treasury yields, global 10-years
- China AI bust threatens Xi’s ’Wall Street East’ ambitions
- Hold up — I had a great time talking to the RIAA guy